Monthly information on share capital and company voting rights

Rhea-AI Summary

Cellectis announced its share and voting rights update as of October 31, 2021. The total number of shares in circulation is 45,475,310, while the total number of voting rights stands at 51,076,779. As a gene editing company, Cellectis focuses on CAR-T therapies for oncology and has 21 years of expertise in the field. Its approach includes off-the-shelf gene-edited CAR T-cells and a new platform targeting hemopoietic stem cells for various diseases. Cellectis is listed on Nasdaq (ticker: CLLS) and Euronext Growth (ticker: ALCLS).

Positive

• Cellectis has a total of 45,475,310 shares in circulation, indicating a stable equity structure.
• The company reported 51,076,779 voting rights, reflecting shareholder engagement.

Negative

• None.

(Article 223-16 of General Regulation of the French financial markets authority)

NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

Date	Total number of shares in the capital	Total number of voting rights
10/31/2021	45,475,310	51,076,779

About Cellectis
Cellectis is a gene editing company, developing first of its kind therapeutic products. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 21 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs.
As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing lifesaving UCART product candidates for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM). .HEAL is a new platform focusing on hemopoietic stem cells to treat blood disorders, immunodeficiencies and lysosomial storage diseases.
Cellectis headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).

For more information, visit www.cellectis.com   
Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.

For further information, please contact:

Media contacts:
Pascalyne Wilson, Director, Communications, +33776991433, media@cellectis.com

Investor Relation contact:
Eric Dutang, Chief Financial Officer, +1 (646) 630 1748, investor@cellectis.com 

Attachment

• Voting_Rights_PR_October_EN.pdf

FAQ

What is the total number of shares for Cellectis as of October 31, 2021?

Cellectis has a total of 45,475,310 shares in circulation as of October 31, 2021.

How many voting rights does Cellectis have?

Cellectis has a total of 51,076,779 voting rights.

What is Cellectis's stock symbol on Nasdaq?

Cellectis is listed on Nasdaq under the stock symbol CLLS.

What is the main focus of Cellectis in the biotech industry?

Cellectis focuses on developing CAR-T immunotherapies for oncology and therapeutic gene editing.